Open Orphan signs new 2-year contract with a tier 1 German pharmaceutical company

Open Orphan plc (LON:ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials, has announced a new 2-year contract with a tier 1 German pharmaceutical company which is one of Europe’s top research-driven pharmaceutical companies.  

The contract guarantees annual revenue, for the next two years, with work under the contract to commence this month. The contract will see the Venn Life Sciences, part of Open Orphan plc, Breda office in the Netherlands, build upon its strong existing relationship with this German pharmaceutical company.

This contract is an extension of the relationship built with the leading German pharmaceutical company. The new contract is in addition to the work currently undertaken by Venn, to the client, providing support in quantitative sciences (pharmacokinetics and pharmacometrics) as well as earlier stage projects.

As pharmacometric analysis is becoming an ever more important part of regulatory submissions, the Venn team in Breda is increasing its specialisation with the ambition of becoming the European leader in pharmacometric analysis.

Cathal Friel, Executive Chairman, Open Orphan, said:

“Open Orphan’s subsidiaries continue to excel, highlighting the well-rounded expertise of the group and in turn maximising shareholder value. This contract delivers on a number of our ambitions, it is a large multi-year contract generating recurring revenues, it is with a large partner and it utilises our expertise in pharmacometric analysis.”

“This new contract further demonstrates Open Orphan’s ability to execute on its significant pipeline of contracts with major pharmaceutical business. It also demonstrates Venn Life Sciences position as a market leader in its field.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Open Orphan PLC

More articles like this

Open Orphan Plc

How human challenge trials can accelerate vaccine development

Human challenge studies provide more valuable information than animal challenge studies, which produce results that must be extrapolated in order to determine the impact on humans. They also allow for trials on a small participant pool that faces

Open Orphan Plc

Considerations on Manufacturing Challenge Agents webinar

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses

Open Orphan Plc

Global leader in Human Challenge vaccine development

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses

Open Orphan Plc

Open Orphan could realise £20 million in first non-core asset IPO

Co-founder Cathal Friel has indicated that a series of spinouts could unlock £750 million for shareholders in the Dublin-based pharma company. Open Orphan, the Dublin-listed pharmaceutical services company run by Cathal Friel, will launch an initial public offering

Open Orphan Plc

Open Orphan considers spinning out assets

Specialist pharmaceutical services clinical research company, Open Orphan, is considering a possible spin-out of certain non-core development intellectual property assets. The company said the potential demerger is at an advanced stage of planning. The assets include HVO-001, a